Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04336943
Title Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors University of Washington
Indications

prostate adenocarcinoma

Therapies

Durvalumab + Olaparib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST